Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy : data from the International Severe Asthma Registry (ISAR)

Funding: ISAR is conducted by OPC Global, and co-funded by OPC Global and AstraZeneca.Peer reviewedPostprin